Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

详细信息    查看全文

• 作者：Michael Anstead^a ; ^{mianst0@uky.edu} ; Sonya L. Heltshe^b ; Umer Khan^c ; Joseph T. Barbieri^d ; Markus Langkamp^e ; Gerd Dö ; ring^f ; Shimoni Dharia^g ; Ronald L. Gibson^b ; Miriam M. Treggiari^h ; James Lymp^c ; Margaret Rosenfeld^b ; Bonnie Ramsey^b
• 关键词：Pseudomonas ; Serology ; Treatment ; Infection ; EPIC
• 刊名：Journal of Cystic Fibrosis
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：12
• 期：2
• 页码：147-153
• 全文大小：423 K

文摘

Background

The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.

Methods

Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.

Results

Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p = 0.003 and p = 0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation.

Conclusion

P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.